Criticism of the company too harsh - well this is information I have known for some time.
It makes my blood boil - ie the performance of this company. Remember Cantrixil and their collaboration with Yale (which the new board promptly cancelled)
Oasmia now called Vivesto has a market cap of the equivalent of A$22 m and no cash. Zero chance of any phase 2 trial (which should of started by now).
So what - but what if I told you......
an aussie company, - lead by Dr Kelly tried to secure the rights to develop Cantrixil - but instead for a lousy $4m, Cantrixil was shipped off to Sweden.
There is clawback provisions under most license agreements like this - the problem is when the company needs to check the calendar to see what day it is - that isn't going to happen.
------------
Solna, Sweden, 28 March 2022 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name,
Vivesto AB, has been registered with the Swedish Companies Registration Office.
-----------------
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian CancerVandana Singh
March 1, 2021·1 min read
Kazia Therapeutics Ltd (NASDAQ:
KZIA) has
entered an exclusive worldwide licensing agreement with
Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cancer.
- The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.
- Oasmia's lead product, Apealea (paclitaxel micellar), is approved in Europe for adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in late-stage development in the U.S.
- Oasmia expects to commence a Phase 2 study of Cantrixil in ovarian cancer in 2022.
- Under the terms of the agreement, Oasmia will make an upfront payment of $4 million to Kazia, with contingent milestone payments of up to $42 million and double-digit royalties on commercial sales.
- Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1, that targets the entire spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) thought to be responsible for disease relapse.
